Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-05-29
2007-05-29
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S012200, C514S051000, C514S277000, C514S851000, C536S026100, C536S025600, C424S045000, C424S427000, C128S898000, C623S004100
Reexamination Certificate
active
10962016
ABSTRACT:
The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The pharmaceutical formulation useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compounds, or hydrolysis-resistant mononucleoside triphosphate salts. The present invention also provides P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5635160 (1997-06-01), Stutts, III et al.
patent: 5763447 (1998-06-01), Jacobus et al.
patent: 5789391 (1998-08-01), Jacobus et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 6040297 (2000-03-01), De Flora et al.
patent: 6258374 (2001-07-01), Friess et al.
patent: 6277855 (2001-08-01), Yerxa
patent: 6319908 (2001-11-01), Yerxa et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: 6348589 (2002-02-01), Pendergast et al.
patent: 6458946 (2002-10-01), Maeda et al.
patent: 6548658 (2003-04-01), Yerxa
patent: 6555675 (2003-04-01), Rideout et al.
patent: 6596725 (2003-07-01), Peterson et al.
patent: 6673779 (2004-01-01), Jacobus et al.
patent: 6696425 (2004-02-01), Yerxa et al.
patent: 6818629 (2004-11-01), Peterson et al.
patent: 7034052 (2006-04-01), Man et al.
patent: 2002/0156269 (2002-10-01), Maeda et al.
patent: 1 191 032 (2002-03-01), None
patent: 1 043 329 (2002-08-01), None
patent: 07-242685 (1995-09-01), None
patent: WO 98/34593 (1998-08-01), None
patent: WO 98/34942 (1998-08-01), None
patent: WO 99/05155 (1999-02-01), None
patent: WO 99/61012 (1999-12-01), None
patent: WO 00/20430 (2000-04-01), None
patent: WO 00/30629 (2000-06-01), None
patent: WO 00/39145 (2000-07-01), None
patent: WO 01/02416 (2001-01-01), None
patent: WO 01/87913 (2001-11-01), None
Maminishkis, et al., “The P2Y2Receptor Agonist INS37217 Stimulates RPE Fluid Transport In Vitro and Retinal Reattachment in Rat,”IOVS, 43(11): 3555-3566 (2002).
International Preliminary Examination Report Oct. 1, 2004 PCT.
Blaug, et al., “P2Y2 receptor agonists induce prolonged calcium, membrane voltage, conductance and fluid absorption increases in bovine RPE,”IOVS, 41(4):S136 (2000) XP001088187.
Burnstock, et al., “P2 purinergic receptors: Modulation of cell function and therapeutic potential,”Journal of Pharmacology and Experimental Therapeutics295(3) 862-869 (2000) XP002208652.
Coste et al., “Non-adenylated Bis(5′-nucleosidyl) Tetraphosphates Occur inSaccharomyces cerevisiaeand inEsherichia coliand Accumulate upon Temperature Shift or Exposure to Cadmium,”Journal of Biological Chemistry, 262(25), 12096-12103 (Sep. 5, 1987).
Ferris, et al., “Oligomerization reactions of deoxyribonucleotides on montmorillonite clay: the effect of mononucleotide structure on phosphodiester bond formation,”Origins Life Evol. Biosphere, 19(6):609-619 (1989) XP001085277.
Maminishkis, et al., “Purinoceptor agonists increase fluid clearance out of subretinal space (SRS) blebs in vivo,”IOVS, 41(4):S136 (2000) XP001083820.
Peterson, et al., “Extracellular ATP activates calcium signaling, ion, and fluid transport in retinal pigment epithelium,”Journal of Neuroscience, 17:(7)2324-2337 (1997) XP001087693.
Sillero, et al., (2′,3′-Dideoxynucleoside triphosphates (ddNTP) and di-2′,3′-dideoxynucleoside tetraphosphates (ddNp4ddN) behave differently to the corresponding NTP and NP4N counterparts as substrates of firefly luciferase, and dinucleoside tetraphosphatase and phosphodiesterases,Biochemica et Biophysica Acta 1334(2-3):191-199 (1997) XP002208651.
Sillero, et al., “Dinucleosidetriphosphatase from Rat Liver—Purification and Properties,”European Journal of Biochemistry, 76(2), 331-337 (Jun. 15, 1977).
Theoclitou, et al., “Characterization of stress protein LysU. Enzyme synthesis of diadenosine 5′,5′”-P1,P4-tetraphosphate (Ap4A) analogs by LysU,J. Chem. Soc., Perkins Trans. 1(16):2009-2019 (1996) XP00108769.
Vallejo et al., “Dinucleosideasetetraphosphatase in Rat Liver andArtemia Selina,” Biochimica et Biophysica Acta, 435, 604-309 (1976).
Williams, M., “P2 Receptros as drug discovery targets,”Am. Chem. Soc. 220th, Medi-185 (2000) XP001085299.
Pendergast William
Peterson Ward M.
Rideout Janet L.
Yerxa Benjamin R.
Howrey LLP
Inspire Pharmaceuticals Inc.
Khare Devesh
LandOfFree
Pharmaceutical formulation comprising dinucleoside... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulation comprising dinucleoside..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulation comprising dinucleoside... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3785274